Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sezary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project [Hematologic Malignancy]

Conclusion
Brentuximab vedotin demonstrated significant clinical activity in treatment-refractory or advanced MF or SS with a wide range of CD30 expression levels. Additional biomarker studies may help optimize rational design of combination therapies with brentuximab vedotin.

Source: Journal of Clinical Oncology - November 6, 2015 Category: Cancer & Oncology Authors: Kim, Tavallaee, Sundram, Salva, Wood, Li, Rozati, Nagpal, Krathen, Reddy, Hoppe, Nguyen-Lin, Weng, Armstrong, Pulitzer, Advani, Horwitz Tags: Diagnosis & Staging, Chemotherapy, Biologic Therapy, Biology & Immunology Hematologic Malignancy Source Type: research